8-week Growth Protocol

RAD-140 SAFETY DATA SHEET
MK-2866 SAFETY DATA SHEET
ENCLOMIPHENE SAFETY DATA SHEET

The 8 Week Growth Protocol is an extended-duration research package assembled for preclinical investigation of full-cycle anabolic signalling and post-administration endocrine recovery. It combines a high-potency SARM with a tissue-selective SARM in dosing quantities sufficient for an eight-week experimental window, paired with enclomiphene for the post-cycle phase studying HPG-axis restoration.

The mechanistic rationale spans both the active and recovery phases of the research model. RAD-140 supplies sustained tissue-selective AR agonism with documented anabolic activity in skeletal muscle and bone, MK-2866 contributes complementary muscle-preserving activity with a milder androgenic profile, and enclomiphene functions as a selective estrogen receptor modulator that elevates LH and FSH to support endogenous testosterone synthesis following the active phase. Together they form a complete framework for studying anabolic signalling alongside structured hormonal recovery.

Included in this protocol:

• 2 × RAD-140 | 100 pellets, 10 mg active compound per pellet
• 2 × MK-2866 | 100 pellets, 10 mg active compound per pellet
• 1 × Enclomiphene | 100 pellets, 10 mg active compound per pellet

Total: 500 pellets / 5,000 mg active compound.

Compound roles in this protocol:

RAD-140 (Testolone) – high-potency non-steroidal SARM providing the primary AR agonism axis throughout the active research phase, with tissue-selective anabolic signalling and absence of estrogenic conversion.

MK-2866 (Ostarine) – tissue-selective SARM contributing complementary muscle-preserving activity with a mild androgenic profile, supporting sustained anabolic signalling across the extended duration.

Enclomiphene – (E)-enantiomer of clomiphene citrate functioning as a selective estrogen receptor modulator, included for the post-administration phase to model restoration of endogenous testosterone synthesis through elevated LH and FSH signalling.

Combined research applications:

• Preclinical models of full-cycle anabolic signalling across an extended eight-week active phase
• Studies of HPG-axis suppression and subsequent recovery following structured AR agonist exposure
• Investigation of lean mass accrual and bone mineral density across long-duration stimulation
• Research into endocrine recovery dynamics following dual-SARM administration
• Comparative analysis of cycle-and-recovery frameworks versus continuous administration models

This protocol is positioned as a complete research framework covering both the active and post-administration phases, designed for investigators requiring a structured cycle-and-recovery model rather than discrete short-duration exposures. The inclusion of enclomiphene allows the recovery phase to be studied with the same rigour as the active phase, supporting comprehensive endocrine research designs.

⚠ Important Note: This product is supplied strictly for laboratory research use only. It is not approved for human consumption or therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease.